Pharmaceuticals

PEI's $32M drug subsidy renewal isn't just about local healthcare—it's a critical financial prototype for Canada's looming national pharmacare rollout.

Astellas Pharma's real-world study uses medical-grade wearables to prove its non-hormonal menopause drug Veozah significantly reduces nighttime awakenings.

JCR Pharmaceuticals and Italfarmaco are teaming up to bring a revolutionary, brain-penetrating Hunter syndrome therapy to Western markets.

As life science supply chains face mounting risks, manufacturers are realizing that a simple labeling error can halt multi-million-dollar production lines.

NORD's latest $145,000 seed funding proves that in the overlooked world of rare diseases, modest philanthropic grants are the ultimate catalyst for innovation.

A new Real-Price Index reveals the hidden fees, dose escalators, and teaser rates in the booming GLP-1 telehealth market, sparking a transparency revolution.

PolyPid has regained European rights to its promising infection-fighting drug. Now begins a high-stakes race to secure a partner before approval.

Radnostix divests its stalled New Mexico nuclear fuel assets to NANO Nuclear for $13.5 million, marking a high-stakes pivot toward medical theranostics.

The NHS rollout of Tryngolza offers a monthly RNA-targeted lifeline for FCS patients, proving the practical value of execution in genetic lipid disorders.

Dunbar Pharmaceuticals has launched the UK’s first plant-derived dronabinol oral spray, signaling a major shift in European biopharma infrastructure.

As GLP-1 drugs face scrutiny for causing lean tissue loss, advanced MRI biomarkers are reshaping clinical trials and the future of metabolic medicine.

GOA Therapeutics is combining venture backing and institutional placements with retail crowdfunding as part of a $300 million strategy to fund its alcohol poisoning antidote candidate.

Novo Nordisk’s new data shows patients successfully switching from injectable GLP-1s to a daily pill. But what does this mean for the $100B obesity market?

As regulatory pressures mount against forever chemicals, TekniPlex Healthcare introduces novel PFAS-free materials to safeguard the next generation of drugs.

As PBM satisfaction stagnates, plan sponsors are weaponizing the RFP process to demand transparency, carve out specialty drugs, and reclaim control.

Kyowa Kirin’s partnership with Knight Therapeutics to bring POTELIGEO to Latin America reveals the complex strategy required to conquer fragmented markets.

Invivyd's VYD2311 beats mRNA vaccines on tolerability and boosts immunity, but regulatory and economic hurdles loom large for the novel therapy.

By trading toxic payloads for precise degradation, Nurix Therapeutics is writing a masterclass in biotech survival and post-merger pharmaceutical strategy.

To unlock the true potential of AI in drug discovery, Big Pharma must first clean its messy data. Novartis just made a massive move to do exactly that.

As GLP-1 drugs boom, a new ancillary market is emerging to treat their side effects. French CDMO ANJAC is building the infrastructure to power it.